William Febbo: Yes. And Rich, this is Will, just add to that, we’ve cut our teeth on patient, right? So our clients already think of us as someone who can help them engage with patients at a highly engaging level with SMS and adherence type work. So a lot of the RFPs in that process, you have to check a bunch of boxes. And one of those boxes is patient. So just keep in mind that everything we’ve been checking for the last three, four months has included patient now we didn’t have anywhere near this capability and now we do. So yes, I agree with everything Steve said. I just wanted know put on that it isn’t a completely new thing for our clients to think of us for patients.
Andrew D’Silva: And just one point of clarification really quickly, sorry, I said on the share count, it’s actually just under $17 million, not just under $18 million.
William Febbo: Great. Thanks, Andy. Better.
Richard Baldry: And Just, when I think about the metrics you kind of call out and focus on you talk a lot about top 20 pharma, somewhere close to 60% of revenues. When you put the two companies together, let’s say one plus one equals two. On a revenue side, does it become far more cost effective to really go after that next group in the top 100 because you can drive a better ARPU out of it to become more sales efficient, to kind of dig into that middle market, more attractive, however you want to think about it. Thanks.
William Febbo: Thanks, Rich. I’ll start and Steve can add. I think still most of the money is in the top 20, right? And the top 20 partners with a lot of the others to supply the commercial and marketing strength. But because of DAAP and because of the way it’s designed, there will be a day when we have turnkey solutions for one product companies, because they’re not going to be able to afford the traditional models, they’re not even as effective. And so I would say in the short term our focus is absolutely the top 20, top 30 manufacturers, top 200 brands, especially focused in specialty medications. But there is a day where we’ll be able to have a model for companies that can’t afford what the top 20 can afford. But they need it.
And we have some of those clients today that actually use our solution to drive their business and they only work with us. I can’t use names, but it’s been highly effective. But yes, now that we’ll have more scale, Steve and his team can put that together.
Steve Silvestro: Yes. I think you covered it. I mean two of those DAAP deals are outside of the top 20. Rich, just to give you an idea and actually what they decided to do was replace their sales force to a large degree with the execution and the deployment of the DAAP model. It’s just way more efficient from a cost perspective.
Richard Baldry: Great, thanks.
William Febbo: Yes. Thanks Rich.
Operator: Thank you. As there are no further questions, I would now hand the conference over to William J. Febbo, CEO for closing comments.
William Febbo: Thank you, Operator. And thank you everyone for joining us this morning. I’m sure you could sense our excitement and see our positive momentum from the second half of 2023 and into 2024. As I say, internally we are back. As we move forward in our financial and operational planning for 2024, we are transitioning into a new year on firm ground. Having significantly enhanced our reach with HCPs and patients enabled by proprietary AI models, the headwinds have largely subsided and we now offer a very focused and holistic solution that pulls everything together into powerful, agile solutions that solve pressing everyday challenges such as brand awareness, adherence, access, affordability and onboarding hard to find patients for HCPs. These are the challenges our clients, doctors and patients face in today’s healthcare system and we are thrilled to play our part.
The Medicx transaction not only positions OptimizeRx to profitably expand our market opportunity, we are also further enhancing our position as a leading player in the digital pharma marketing landscape by meaningfully expanding our channels and reach to unlock value for our customers. Moreover, the transaction is accretive to earnings as Medicx is highly profitable company and is expected to contribute meaningful to revenue, revenue growth, EBITDA and earnings per share. On a combined basis, revenues are expected to quickly surpass $100 million while generating significant profitability and cash flow. We will be working hard to finish the year strong, conduct multiple non-deal roadshows and continue to fine tune our focus to maximize impact.
Five years ago this month we rang the NASDAQ bell as part of our uplift from the OTC and today we will do so again at the close of the markets. It has been an exciting journey up to this point, but we are just getting started as it relates to scale with our clients. That combined with actually helping doctors and patients align on care is what motivates us as a team. And with that, thank you for your time and I look forward to discussing the full year in our Q4 earnings call. Have a great rest of your day everyone. Thank you, Operator.
Operator: Thank you sir. Before we conclude today’s call, I would like to provide the Company’s Safe Harbor statement that includes important cautions regarding forward-looking statements made during today’s call. Statements made by management during today’s call may contain forward looking statements with the definition of Section 27A and the Securities Act of 1933 has amended and Section 21E of the Securities Act of 1934 has amended. These forward looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible and seeking and similar expressions identify forward-looking statements. They may speak only to the date that such statements are made. Such forward looking statements in this call include statements regarding estimation of total addressable, market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology investments, growth opportunities, acquisitions, upcoming announcements and the need for raising additional capital.
